@article {78, editor = {,}, title = {â–¼Insulin degludec for diabetes mellitus}, volume = {51}, number = {7}, pages = {78--81}, year = {2013}, doi = {10.1136/dtb.2013.7.0190}, publisher = {British Medical Journal Publishing Group}, abstract = {Over the last few years there has been a steady increase in the number of prescriptions dispensed in primary care for intermediate and long-acting insulin analogues and a reduction in prescriptions for biphasic isophane insulin. For example, in England, the volume of intermediate and long-acting insulin analogues in general practice has risen from approximately 650,000 prescriptions per quarter in 2007 to over 850,000 per quarter in 2012.1 â–¼Insulin degludec (Tresiba, Novo Nordisk) is a new long acting basal insulin analogue for the management of diabetes mellitus in adults.2 Two strengths of insulin degludec (100 units/mL and 200 units/mL) were launched in the UK in February 2013. Here we discuss evidence for the effectiveness and safety of insulin degludec.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/51/7/78}, eprint = {https://dtb.bmj.com/content/51/7/78.full.pdf}, journal = {Drug and Therapeutics Bulletin} }